June 3rd 2025
Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and quality of life for patients.
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Payment for Pharmacist Services: 2025 Update
1.0 Credit / General Pharmacy, Health Equity, Diversity & Inclusion, Law
View More
Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists
1.5 Credits / Genitourinary Cancer, Men's Health, Oncology
View More
Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care
2.0 Credit / Genitourinary Cancer, Men's Health, Oncology
View More
FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
May 20th 2020The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior treatment with enzalutamide or abiraterone.
Read More
USPSTF Recommends Patient Choice for Prostate Cancer Screening
May 11th 2018The US Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make their own decision on whether or not to be screened periodically for prostate cancer after they have had a conversation with their physician on potential benefits and harms.
Read More